logo-loader
viewGenedrive PLC

genedrive PLC unveils 15-minute COVID-19 point-of-care test direct from saliva

The simplicity and speed of the test mean results can be delivered while the patient waits, rather than material having to be shipped and then assessed, which takes at least 24 hours

Genedrive PLC -

genedrive PLC (LON:GDR) said it is now generating “very promising data” from its coronavirus (COVID-19) test, targeted for release in the first quarter of next year, having recently completed the assay design.

Using the point-of-care technology, results can be generated in 15 minutes for a positive sample, while a negative takes five minutes longer.

The kit has been developed to detect SARS-CoV-2 amplified directly from saliva without the need to extract viral RNA.

The simplicity and speed of the test mean results can be delivered while the patient waits, rather than material having to be shipped and then assessed, which takes at least 24 hours.

The full release of the final CE-marked product is expected in the first quarter of next year.

"Rapid testing for current infection is a cornerstone to any track and trace programme, to quickly accessing current infection, to limiting infection, and to giving assurance to people concerned about their status,” said David Budd, genedrive’s chief executive in a statement.

“We believe the Genedrive POC solution can contribute significantly to the ongoing management of this global health crisis."

In the same announcement, the company said it is working on a “version-two” advance would accept a freeze-dried PCR bead format previously developed for the high throughput Genedrive 96 SARS-CoV-2 Kit.

This would allow for lower production costs and “highly scalable manufacturing capacity”, investors were told.

"Genedrive add that the current POC test reads out a positive sample in circa 15 minutes (and a fully negative result achieved in circa 20 minutes) with the limit of detection being in line with the UK’s MHRA Target Product Profile sensitivity requirements (over 98%, we understand)," analysts at house broker Peel Hunt commented.

--Adds analysts comment--

 

Quick facts: Genedrive PLC

Price: 57 GBX

AIM:GDR
Market: AIM
Market Cap: £32.18 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: FTSE falls as hopes of US stimulus package before election wanes

FTSE 100 opened lower amid continued scepticism about a US stimulus package before next month’s election. London’s index of big caps dived 40 points to 5,735 in early trading.   Chancellor Rishi Sunak is expected to announce more support for workers in areas placed under tier 2 of local...

on 22/10/20

2 min read